Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia

Standard

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. / Gratwohl, Alois; Duarte, Rafael; Snowden, John A; van Biezen, Anja; Baldomero, Helen; Apperley, Jane; Cornelissen, Jan; Greinix, Hildegard T; Grath, Eoin Mc; Mohty, Mohamad; Kroeger, Nicolaus; Nagler, Arnon; Niederwieser, Dietger; Putter, Hein; Brand, Ronald; Joint Accreditation Committee JACIE.

in: ECLINICALMEDICINE, Jahrgang 15, 10.2019, S. 33-41.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Gratwohl, A, Duarte, R, Snowden, JA, van Biezen, A, Baldomero, H, Apperley, J, Cornelissen, J, Greinix, HT, Grath, EM, Mohty, M, Kroeger, N, Nagler, A, Niederwieser, D, Putter, H, Brand, R & Joint Accreditation Committee JACIE 2019, 'Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia', ECLINICALMEDICINE, Jg. 15, S. 33-41. https://doi.org/10.1016/j.eclinm.2019.07.019

APA

Gratwohl, A., Duarte, R., Snowden, J. A., van Biezen, A., Baldomero, H., Apperley, J., Cornelissen, J., Greinix, H. T., Grath, E. M., Mohty, M., Kroeger, N., Nagler, A., Niederwieser, D., Putter, H., Brand, R., & Joint Accreditation Committee JACIE (2019). Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. ECLINICALMEDICINE, 15, 33-41. https://doi.org/10.1016/j.eclinm.2019.07.019

Vancouver

Bibtex

@article{9699e523b11c4644968656d5eb38ebb1,
title = "Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia",
abstract = "Background: The role of conditioning intensity and stem cell source on modifying pre-transplantation risk in allogeneic haematopoietic stem cell transplantation (HSCT) is a matter of debate, but crucial when benchmarking centres.Methods: This Retrospective, multicenter exploratory-validation analysis of 9103 patients, (55.5% male, median age 50 years; 1-75 years range) with an allogeneic HSCT between 2010 and 2016 from a matched sibling (N = 8641; 95%) or matched unrelated donor (N = 462; 5%) for acute myeloid (N = 6432; 71%) or acute lymphoblastic (N = 2671; 29%) leukaemia in first complete remission, and reported by 240 centres in 30 countries to the benchmark database of the European Society for Blood and Marrow Transplantation (EBMT) searched for factors associated with use of transplant techniques (standard N = 6375;70% or reduced intensity conditioning N = 2728;30%, respectively bone marrow N = 1945;21% or peripheral blood N = 7158;79% as stem cell source), and their impact on outcome.Findings: Treatment groups differed significantly from baseline population (p < 0.001), and within groups regarding patient-, disease-, donor-, and centre-related pre-transplantation risk factors (p < 0.001); choice of technique did depend on pre-transplantation risk factors and centre (p < 0.001). Probability of overall survival at 5 years decreased systematically and significantly with increasing pre-transplantation risk score (score 2 vs 0/1 HR: 1·2, 95% c.i. [1·1-1·.3], p = 0.002; score 3 vs 0/1 HR: 1·5, 95% c.i. [1·3-1·7], p < 0.001; score 4/5/6 vs 0/1 HR: 1·9, 95% c.i. [1·6-2·2], p < 0.001) with no significant differences between treatment groups (likelihood ratio test on interaction: p = 0.40). Overall survival was significantly associated with selection steps and completeness of information (p < 0.001).Interpretation: Patients' pre-transplantation risk factors determine survival, independent of transplant techniques. Transplant techniques should be regarded as centre policy, not stratification factor in benchmarking. Selection criteria and completeness of data bias outcome. Outcomes may be improved more effectively through better identifying pre-transplantation factors as opposed to refinement of transplant techniques.Funding: The study was funded by EBMT.",
author = "Alois Gratwohl and Rafael Duarte and Snowden, {John A} and {van Biezen}, Anja and Helen Baldomero and Jane Apperley and Jan Cornelissen and Greinix, {Hildegard T} and Grath, {Eoin Mc} and Mohamad Mohty and Nicolaus Kroeger and Arnon Nagler and Dietger Niederwieser and Hein Putter and Ronald Brand and {Joint Accreditation Committee JACIE}",
note = "{\textcopyright} 2019 Published by Elsevier Ltd.",
year = "2019",
month = oct,
doi = "10.1016/j.eclinm.2019.07.019",
language = "English",
volume = "15",
pages = "33--41",
journal = "ECLINICALMEDICINE",
issn = "2589-5370",
publisher = "Lancet Publishing Group",

}

RIS

TY - JOUR

T1 - Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia

AU - Gratwohl, Alois

AU - Duarte, Rafael

AU - Snowden, John A

AU - van Biezen, Anja

AU - Baldomero, Helen

AU - Apperley, Jane

AU - Cornelissen, Jan

AU - Greinix, Hildegard T

AU - Grath, Eoin Mc

AU - Mohty, Mohamad

AU - Kroeger, Nicolaus

AU - Nagler, Arnon

AU - Niederwieser, Dietger

AU - Putter, Hein

AU - Brand, Ronald

AU - Joint Accreditation Committee JACIE

N1 - © 2019 Published by Elsevier Ltd.

PY - 2019/10

Y1 - 2019/10

N2 - Background: The role of conditioning intensity and stem cell source on modifying pre-transplantation risk in allogeneic haematopoietic stem cell transplantation (HSCT) is a matter of debate, but crucial when benchmarking centres.Methods: This Retrospective, multicenter exploratory-validation analysis of 9103 patients, (55.5% male, median age 50 years; 1-75 years range) with an allogeneic HSCT between 2010 and 2016 from a matched sibling (N = 8641; 95%) or matched unrelated donor (N = 462; 5%) for acute myeloid (N = 6432; 71%) or acute lymphoblastic (N = 2671; 29%) leukaemia in first complete remission, and reported by 240 centres in 30 countries to the benchmark database of the European Society for Blood and Marrow Transplantation (EBMT) searched for factors associated with use of transplant techniques (standard N = 6375;70% or reduced intensity conditioning N = 2728;30%, respectively bone marrow N = 1945;21% or peripheral blood N = 7158;79% as stem cell source), and their impact on outcome.Findings: Treatment groups differed significantly from baseline population (p < 0.001), and within groups regarding patient-, disease-, donor-, and centre-related pre-transplantation risk factors (p < 0.001); choice of technique did depend on pre-transplantation risk factors and centre (p < 0.001). Probability of overall survival at 5 years decreased systematically and significantly with increasing pre-transplantation risk score (score 2 vs 0/1 HR: 1·2, 95% c.i. [1·1-1·.3], p = 0.002; score 3 vs 0/1 HR: 1·5, 95% c.i. [1·3-1·7], p < 0.001; score 4/5/6 vs 0/1 HR: 1·9, 95% c.i. [1·6-2·2], p < 0.001) with no significant differences between treatment groups (likelihood ratio test on interaction: p = 0.40). Overall survival was significantly associated with selection steps and completeness of information (p < 0.001).Interpretation: Patients' pre-transplantation risk factors determine survival, independent of transplant techniques. Transplant techniques should be regarded as centre policy, not stratification factor in benchmarking. Selection criteria and completeness of data bias outcome. Outcomes may be improved more effectively through better identifying pre-transplantation factors as opposed to refinement of transplant techniques.Funding: The study was funded by EBMT.

AB - Background: The role of conditioning intensity and stem cell source on modifying pre-transplantation risk in allogeneic haematopoietic stem cell transplantation (HSCT) is a matter of debate, but crucial when benchmarking centres.Methods: This Retrospective, multicenter exploratory-validation analysis of 9103 patients, (55.5% male, median age 50 years; 1-75 years range) with an allogeneic HSCT between 2010 and 2016 from a matched sibling (N = 8641; 95%) or matched unrelated donor (N = 462; 5%) for acute myeloid (N = 6432; 71%) or acute lymphoblastic (N = 2671; 29%) leukaemia in first complete remission, and reported by 240 centres in 30 countries to the benchmark database of the European Society for Blood and Marrow Transplantation (EBMT) searched for factors associated with use of transplant techniques (standard N = 6375;70% or reduced intensity conditioning N = 2728;30%, respectively bone marrow N = 1945;21% or peripheral blood N = 7158;79% as stem cell source), and their impact on outcome.Findings: Treatment groups differed significantly from baseline population (p < 0.001), and within groups regarding patient-, disease-, donor-, and centre-related pre-transplantation risk factors (p < 0.001); choice of technique did depend on pre-transplantation risk factors and centre (p < 0.001). Probability of overall survival at 5 years decreased systematically and significantly with increasing pre-transplantation risk score (score 2 vs 0/1 HR: 1·2, 95% c.i. [1·1-1·.3], p = 0.002; score 3 vs 0/1 HR: 1·5, 95% c.i. [1·3-1·7], p < 0.001; score 4/5/6 vs 0/1 HR: 1·9, 95% c.i. [1·6-2·2], p < 0.001) with no significant differences between treatment groups (likelihood ratio test on interaction: p = 0.40). Overall survival was significantly associated with selection steps and completeness of information (p < 0.001).Interpretation: Patients' pre-transplantation risk factors determine survival, independent of transplant techniques. Transplant techniques should be regarded as centre policy, not stratification factor in benchmarking. Selection criteria and completeness of data bias outcome. Outcomes may be improved more effectively through better identifying pre-transplantation factors as opposed to refinement of transplant techniques.Funding: The study was funded by EBMT.

U2 - 10.1016/j.eclinm.2019.07.019

DO - 10.1016/j.eclinm.2019.07.019

M3 - SCORING: Journal article

C2 - 31709412

VL - 15

SP - 33

EP - 41

JO - ECLINICALMEDICINE

JF - ECLINICALMEDICINE

SN - 2589-5370

ER -